Aclaris Therapeutics (ACRS) Invested Capital (2017 - 2022)

Aclaris Therapeutics' (ACRS) quarterly Invested Capital came in at $2.7 million in Q3 2022, down 12.2% year-on-year from $3.1 million in Q3 2021, and little changed quarter-over-quarter from $2.7 million in Q2 2022.

Aclaris Therapeutics (ACRS) Invested Capital (2017 - 2022) Analysis & Trends

Aclaris Therapeutics' Invested Capital history runs 3 years deep, the most recent figure standing at $2.7 million for Q3 2022.

  • On a quarterly basis, Invested Capital fell 12.2% year-over-year to $2.7 million in Q3 2022; TTM through Jun 2023 was $2.7 million, a 75.73% decrease from a year earlier, with the FY2021 full-year figure at $2.6 million, changed N/A from the prior year.
  • Invested Capital steadied at $2.7 million in Q3 2022 per ACRS's latest filing, from $2.7 million in the prior quarter.
  • Across five years, Invested Capital topped out at $3.1 million in Q2 2021 and bottomed at $2.6 million in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.96 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 116.14 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Aclaris Therapeutics 705.88 Mn 705.88 Mn 1.60 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2022 2.70 Mn
Jun 30, 2022 2.70 Mn
Mar 31, 2022 2.70 Mn
Dec 31, 2021 2.65 Mn
Sep 30, 2021 3.08 Mn
Jun 30, 2021 3.08 Mn
Dec 31, 2017 590,000.00